Zobrazeno 1 - 10
of 29
pro vyhledávání: '"LeAnne T Bloedon"'
Autor:
Ulrich Laufs, Maciej Banach, G. B. John Mancini, Daniel Gaudet, LeAnne T. Bloedon, Lulu Ren Sterling, Stephanie Kelly, Erik S. G. Stroes
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 7 (2019)
Background Inability to tolerate statins because of muscle symptoms contributes to uncontrolled cholesterol levels and insufficient cardiovascular risk reduction. Bempedoic acid, a prodrug that is activated by a hepatic enzyme not present in skeletal
Externí odkaz:
https://doaj.org/article/2f1c02e8e5274f348c35a1f0d855216e
Autor:
John S. Millar, Katsunori Ikewaki, LeAnne T. Bloedon, Megan L. Wolfe, Philippe O. Szapary, Daniel J. Rader
Publikováno v:
Journal of Lipid Research, Vol 52, Iss 1, Pp 136-142 (2011)
Treatment with the peroxisome proliferator-activated receptor γ agonist rosiglitazone has been reported to increase HDL-cholesterol (HDL-C) levels, although the mechanism responsible for this is unknown. We sought to determine the effect of rosiglit
Externí odkaz:
https://doaj.org/article/123e5dd4d7c047bcaf75003d50f622b3
Autor:
LeAnne T. Bloedon, Richard Dunbar, Danielle Duffy, Paula Pinell-Salles, Robert Norris, Bruce J. DeGroot, Rajesh Movva, Mohamad Navab, Alan M. Fogelman, Daniel J. Rader
Publikováno v:
Journal of Lipid Research, Vol 49, Iss 6, Pp 1344-1352 (2008)
Patients with coronary heart disease or equivalent risk received a single dose of 30, 100, 300, or 500 mg of unformulated D-4F (n = 8, each dose) or placebo (n = 8) under fasting conditions. An additional 10 patients received 500 mg (n = 8) or placeb
Externí odkaz:
https://doaj.org/article/6a2a993b097a4f0f83e619247f4e7b97
Autor:
Ulrich Laufs, Christie M Ballantyne, Maciej Banach, Harold Bays, Alberico L. Catapano, P. Barton Duell, Anne C. Goldberg, Antonio M. Gotto, Lawrence A. Leiter, Kausik K. Ray, LeAnne T. Bloedon, Diane MacDougall, Yang Zhang, G. B. John Mancini
Publikováno v:
Journal of clinical lipidology. 16(3)
Despite the high incidence of patients with statin tolerance problems, randomized evaluations of nonstatin oral treatment options for lowering of low-density lipoprotein cholesterol (LDL-C) in this population are sparse.To assess the LDL-C lowering e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8f4bfdd2edcf7fe0911c4136d2b9f23
https://pubmed.ncbi.nlm.nih.gov/35346603
https://pubmed.ncbi.nlm.nih.gov/35346603
Autor:
Paula L. Robinson, Christie M. Ballantyne, Alberico L. Catapano, Lulu R. Sterling, Harold Bays, LeAnne T. Bloedon, Narendra D. Lalwani, Kausik K. Ray
Publikováno v:
New England Journal of Medicine. 380:1022-1032
BACKGROUND Short-term studies have shown that bempedoic acid, an inhibitor of ATP citrate lyase, reduces levels of low-density lipoprotein (LDL) cholesterol. Data are limited regarding the safety and efficacy of bempedoic acid treatment in long-term
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::517c7905198287f4c8dc5bafb4e53194
https://doi.org/10.1056/nejmoa1803917
https://doi.org/10.1056/nejmoa1803917
Autor:
Mohamad Navab, Robert B. Norris, Alan M. Fogelman, Daniel J. Rader, Danielle Duffy, Rajesh Movva, LeAnne T. Bloedon, Richard L. Dunbar
Publikováno v:
Clinical and Translational Science
A single dose of the apolipoprotein (apo)A‐I mimetic peptide D‐4F rendered high‐density lipoprotein (HDL) less inflammatory, motivating the first multiple‐dose study. We aimed to assess safety/tolerability, pharmacokinetics, and pharmacodynam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::440716b65bf3ec2df5709d4deabae7d7
https://doi.org/10.1111/cts.12487
https://doi.org/10.1111/cts.12487
Autor:
Dominique Larrey, Daniel J. Rader, Pamela Foulds, Claudia Stefanutti, Emma A. Meagher, LeAnne T. Bloedon, Daniel Gaudet, Dirk J. Blom, Maurizio Averna, Cesare R. Sirtori, Giovanni Battista Vigna, Robert A. Hegele, Marina Cuchel, Hendrik Du Toit Theron, Prediman K. Shah
Publikováno v:
Circulation. 136:332-335
Homozygous familial hypercholesterolemia is a genetic disorder characterized by low-density lipoprotein (LDL)-receptor dysfunction, markedly elevated levels of LDL-cholesterol (LDL-C) and premature atherosclerosis. Patients are often poorly responsiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0d35aca32211aaf8535ef09ded7a5e4
https://doi.org/10.1161/circulationaha.117.028208
https://doi.org/10.1161/circulationaha.117.028208
Autor:
Marina Cuchel, Richard L. Dunbar, Rajesh Movva, Ram Gadi, Danielle Duffy, LeAnne T. Bloedon, Sony Tuteja
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 34:227-239
Study Objective To characterize the effects of two doses (10 and 60 mg) of lomitapide—a microsomal triglyceride transfer protein inhibitor approved as adjunct treatment to lower low-density lipoprotein cholesterol levels in patients with homozygous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::599f67988f3cc9db0fba8876e906e5e4
https://doi.org/10.1002/phar.1351
https://doi.org/10.1002/phar.1351
Autor:
Rand L. Rothman, Debbie L. Cohen, Christine Mayor, Sheri Volger, Mary Lou Galantino, LeAnne T. Bloedon, Raymond R. Townsend, John T. Farrar, Phillipe Szapary
Publikováno v:
Evidence-based Complementary and Alternative Medicine : eCAM
Evidence-Based Complementary and Alternative Medicine, Vol 2011 (2011)
Evidence-Based Complementary and Alternative Medicine, Vol 2011 (2011)
The prevalence of prehypertension and Stage 1 hypertension continues to increase despite being amenable to non-pharmacologic interventions. Iyengar yoga (IY) has been purported to reduce blood pressure (BP) though evidence from randomized trials is l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcce4c7d4553d41cac24b5b1e812aeaa
https://doi.org/10.1093/ecam/nep130
https://doi.org/10.1093/ecam/nep130
Autor:
Richard A. Anderson, Serena Cardillo, Nayyar Iqbal, Philippe Szapary, Raymond C. Boston, LeAnne T. Bloedon, Sheri Volger
Publikováno v:
Metabolic Syndrome and Related Disorders. 7:143-150
The use of chromium-containing dietary supplements is widespread among patients with type 2 diabetes. Chromium's effects in patients at high risk for developing diabetes, especially those with metabolic syndrome, is unknown. The objective of this stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bceefcf4dbc40a85b689553754805d6
https://doi.org/10.1089/met.2008.0048
https://doi.org/10.1089/met.2008.0048